Fig. 2: Data extracted from previous studies implicate the superiority of NGS in discriminating MLCs.
From: Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution
A Conclusive rates of the clinical criterion (Martini-Melamed criteria and proposals in the American Joint Committee on Cancer (AJCC) staging system), pathology and NGS (Empirical &Bioinformatic interpretation of sequencing results) of different coverages subsampled from the extracted sequencing data (sub3genes, etc). These charts were separated according to the panels (below 10 genes, etc) used in the original articles. B Summary of discrimination results of different mimicked panels. C The effects of the coverage excluding the 50 genes (sub50 genes or non 50 genes) compared with the 50-genes panel. The results were changed in 21 cases. D Overlaps between the genes covered by most NGS panels and the genes mutated frequently in MLCs. The number of mutations located on a specific gene is defined as the total number of selected mutations divided by the proportion of mutated cases in all cases where the corresponding gene was sequenced. The diagnosis of the different methods applied to each patient in included studies is presented in tabular form (Supplementary Tables 3 and 4). MLCs multiple lung cancers, MPLC multiple primary lung cancers, IPM intrapulmonary metastasis.
